Marcus Koch

Associate Professor

University of Calgary

Canada

Research Interests

Explore related searches

Professors in Canada

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Articles (15)

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Collaborators (6)

Gary Cutter

UNITED STATES

View details

Marcus Koch

Heidelberg University

GERMANY

View details

Jerry Wolinsky

Emeritus Professor in Neurology

The University of Texas Health Science Center at Houston

UNITED STATES

View details

Ruth Ann Marrie

University of Manitoba

CANADA

View details

Luis Brieva Ruiz

Head of the department

Hospital Universitari Arnau de Vilanova

SPAIN

View details

Maria Pia Sormani

University of Genova

ITALY

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Marcus Koch

Research Interests

Explore related searches

Contact this professor

Articles (15)

Biomarkers of disability worsening in inactive primary progressive multiple sclerosis

Association between age and inflammatory disease activity on magnetic resonance imaging in relapse onset multiple sclerosis during long-term follow-up

Longitudinal Changes in Cognitive Test Scores in Patients With Relapsing-Remitting Multiple Sclerosis An Analysis of the DECIDE Dataset

Threshold definitions for significant change on the timed 25-foot walk and nine-hole peg test in primary progressive multiple sclerosis

Improving the efficiency of clinical trials in multiple sclerosis

Association of age and inflammatory disease activity in the pivotal natalizumab clinical trials in relapsing-remitting multiple sclerosis

Prospective trial of natalizumab personalised extended interval dosing by therapeutic drug monitoring in relapsing-remitting multiple sclerosis (NEXT-MS)

Relapse recovery in relapsing-remitting multiple sclerosis: An analysis of the CombiRx dataset

The nine hole peg test as an outcome measure in progressive MS trials.

Tumor Necrosis Factor α Blockers and the Risk of Multiple Sclerosis.

Serum neurofilament-light and glial fibrillary acidic protein levels in hydroxychloroquine-treated primary progressive multiple sclerosis.

The MSIS-29 and SF-36 as outcomes in secondary progressive MS trials.

The timed 25-foot walk is a more sensitive outcome measure than the EDSS for PPMS trials: an analysis of the PROMISE clinical trial dataset.

Impact of clinical outcomes and imaging measures on health-related quality of life in secondary progressive MS.

Serum HGF and APN2 are associated with disability worsening in SPMS.

Collaborators (6)

Gary Cutter

Marcus Koch

Jerry Wolinsky

Ruth Ann Marrie

Luis Brieva Ruiz

Maria Pia Sormani

Make your next move.